PRIMARY STUDY

Endocannabinoid System in Polycystic Kidney Disease

Key Findings:  Based on finding from their study the authors posit that patients with autosomal dominant polycystic kidney disease have lower levels of endocannabinoids (when compared to healthy people) and that re-establishing endocannabinoid balance (via augmentation of AEA, PEA, and 2-AG levels) may present a novel therapeutic target in this patient population.